目的 探讨18F-FDG PET/CT在初诊小细胞肺癌(SCLC)分期及预后评估中的价值.方法 收集15例经病理证实的初诊SCLC患者作为研究对象,随访其生存期.将患者按经典临床分期分为局限期与广泛期,并测定原发灶最大标准摄取值(SUVmax),以其中位数为界将患者分为两组,分析经典临床分期及SUVmax与生存期之间的关系.结果 15例患者中,18F-FDG PET/CT诊为局限期8例,广泛期7例,与经典临床分期方法相比,改变了3例(3/15,20.00%)的分期,其中2例分期提高,1例分期降低.局限期患者生存期高于广泛期(中位生存期分别为24和11个月,P=0.004);以SUVmax中位数12.40为界,高值组(SUVmax≥12.40)与低值组(SUVmax<12.40)患者生存期差异无统计学意义(中位生存期分别为20和14个月,P=0.343).结论 18F-FDG PET/CT对于初诊SCLC的精确分期、指导治疗和评估预后有重要价值;SUVmax在SCLC患者预后评估中的价值仍需进一步研究.%Objective To explore the value of 18 F-FDG PET/CT in staging and prognosis prediction in patients with newly diagnosed small cell lung cancer (SCLC). Methods Totally 15 patients with newly diagnosed and pathologically proven SCLC were collected and followed up. The patients were staged as limited disease (LD) and extensive disease (ED), and were divided into two groups bounded by the median of the primary tumor maximum standard uptake value (SUVmax. The relation among staging, SUVmax and survival time were analyzed. Results In 15 patients, ED was found in 7, while LD was found in the other 8 patients. 18F-FDG PET/CT altered staging in 3 patients (3/15, 20. 00％), in which 2 were upstaged and 1 was downstaged. Patients with LD had longer overall survival than those with ED (the median survival time was 24 and 11 months, respectively, P= 0. 004). However there was no difference between SUVmax ≥12. 40 cases and SUVmax＜12. 40 cases (the median survival time was 20 and 14 months, respectively, P=0. 343). Conclusion 18F-FDG PET/CT is useful for the staging and management in patients with newly diagnosed SCLC, but the value of SUVmax in prognosis prediction needs further investigation.
展开▼
